KeifeRx entered into a research collaboration and option agreement with Amneal Pharmaceuticals (AMRX) to support the pre-IND development of KFRX06, KeifeRx’s preclinical candidate designed to inhibit leucine-rich repeat kinase 2, a gene strongly implicated in Parkinson’s disease biology. Under the agreement, KeifeRx will conduct a research program intended to generate key pre-IND outputs to support Amneal’s evaluation of KFRX06 and inform potential next-stage development. Financial terms of the agreement were not disclosed.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRX:
- Amneal Pharmaceuticals price target raised to $15 from $14 at Truist
- Amneal Pharmaceuticals announces FDA approval for Boncresa, Oziltus BLAs
- Amneal Pharmaceuticals announces FDA approval for epinephrine injection vials
- Amneal Pharmaceuticals initiated with an Overweight at Barclays
- Amneal Pharmaceuticals announces results from Phase 4 ELEVATE-PD